Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alcon Investigational Agent · 3 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Alcon Investigational Agent | DRUG | - |
Adult subjects of either sex and any race with open-angle glaucoma or ocular hypertension; visual acuity of 20/80 to 20/400 or better (Snellen equivalent) or logMAR visual acuity not worse than 0.6. Clinically relevant ophthalmic or systemic conditions may be excluded.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |
Alcon Investigational Agent is a small molecule being studied for lowering intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. It is an investigational therapy in Phase 3 clinical development, though the three Phase 3 trials listed have been completed.
Alcon Investigational Agent is being developed by Alcon Inc., a company traded on the New York Stock Exchange under the ticker ALC. Alcon is an ophthalmology-focused company, and this agent is being studied for use in open-angle glaucoma and ocular hypertension.
Alcon Investigational Agent is in Phase 3 clinical development. Three Phase 3 trials have been completed, all evaluating its effect on lowering intraocular pressure in patients with open-angle glaucoma and ocular hypertension. It remains an investigational agent and is not yet approved.
Alcon Investigational Agent has been studied in three completed Phase 3 trials: NCT00047515, NCT00047528, and NCT00047541. All three were randomized, double-blind studies conducted in the United States, enrolling adults aged 18 years and older with open-angle glaucoma or ocular hypertension.
Alcon Investigational Agent is a small molecule designed to lower intraocular pressure in patients with open-angle glaucoma and ocular hypertension. The specific molecular target has not been disclosed, but the therapy is intended to reduce IOP, which is a key modifiable risk factor in glaucoma progression.